Treatment for primary biliary cholangitis
The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.
1. A method of treating primary biliary cholangitis, comprising administering orally and once daily to a human in need thereof about 2 mg or about 4 mg of saroglitazar magnesium salt, to treat the primary biliary cholangitis; wherein saroglitazar is represented by:
2. The method of claim 1 , wherein about 4 mg saroglitazar magnesium salt is administered.
3. The method of claim 1 , wherein about 2 mg saroglitazar magnesium salt is administered.
4. The method of claim 1 , wherein saroglitazar magnesium salt is the sole therapeutic agent for treating the primary biliary cholangitis.
5. The method of claim 1 , wherein administering occurs for at least 16 weeks.
6. A method of treating primary biliary cholangitis, comprising administering orally and once daily to a human in need thereof a pharmaceutical formulation in the form of a tablet or a capsule, the pharmaceutical formulation comprising about 2 mg or about 4 mg of saroglitazar magnesium salt; and a pharmaceutical excipient, to treat the primary biliary cholangitis; wherein saroglitazar is represented by:
7. The method of claim 6 , wherein saroglitazar magnesium salt is the sole therapeutic agent in the pharmaceutical formulation.
8. The method of claim 6 , wherein saroglitazar magnesium salt is the sole therapeutic agent for treating the primary biliary cholangitis.
9. The method of claim 6 , wherein the pharmaceutical formulation comprises about 2 mg saroglitazar magnesium salt.
10. The method of claim 6 , wherein the pharmaceutical formulation comprises about 4 mg saroglitazar magnesium salt.